Publication | Open Access

De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial

Hematological MalignancyInterim AnalysisMedicineChronic Myeloid LeukaemiaMixed-phenotype Acute LeukemiaHematologyPharmacologyPharmacotherapyOncologyCancer ResearchMyeloid Neoplasia